All In Biotech

Drug Trial Radar · NCT05192486

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Actual

Start

Aug 10, 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.
First posted
Jan 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

  • GNC-038Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose of GNC-038
  2. Maximum tolerated dose (MTD) or maximum administrated dose (MAD)Time frame: Up to 21 days after the first dose of GNC-038
  3. Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
  4. The recommended dose for phase II clinical study(RP2D)Time frame: Up to 21 days after the first dose of GNC-038

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.